CONSORT 2025 for Reviewers: A Practical Checklist for Interpretable Trials
Anas H. Alzahrani, MD PhD MPH
Department of Preventive Medicine and Public Health
Faculty of Medicine, King Abdulaziz University
A randomized trial can be genuinely randomized and still be difficult to interpret. The allocation may be credible, but the report may not tell you what participants were actually assigned to, which outcomes were measured when, how treatment switching was handled, or why some participants disappeared from the analysis.
That is the problem CONSORT 2025 is designed to address. It is a minimum reporting standard for randomized trials: a 30-item checklist plus a participant-flow diagram, with an expanded checklist that spells out the critical details. It is not a quality score, a substitute for risk-of-bias assessment, or a guarantee that the trial answered its clinical question well.
What CONSORT 2025 Changes — and What It Does Not
The 2025 statement supersedes CONSORT 2010. It adds seven checklist items, revises three, removes one, and introduces a new open-science section. The update is meant to make trial reports more transparent in light of modern practice, including clearer descriptions of intervention delivery, analysis, participant flow, and access to supporting research materials.
The scope still matters. The core statement focuses on the common two-group parallel randomized trial. Cluster, non-inferiority, pragmatic, harms, patient-reported outcome, and other designs may require a relevant CONSORT extension. A report can follow the core checklist and still omit the design-specific information needed for a fair appraisal.
The reviewer’s distinction
“Not reported” means the reader cannot verify a detail. It does not automatically mean “not done.” Keep reporting quality, conduct quality, and statistical validity as separate judgments.
Interactive reviewer triage
What should you ask for first?
Choose the reporting domain that feels weakest. The result is a review action, not a CONSORT score.
First read: Interpretability risk
If eligibility, recruitment, or sequence generation is unclear, the randomization claim cannot be fully reconstructed.
Ask: Can I reconstruct who was eligible, who was randomized, and when assignment happened?
Review action: Request the participant flow, recruitment dates, eligibility rules, allocation sequence, and concealment details before interpreting baseline balance or generalizability.
This simplified teaching aid focuses attention. Use the full CONSORT 2025 checklist and the relevant extension for the trial design.
Seven Reporting Checks with Consequences
Use CONSORT as a map of what must be visible. The important question is not whether a box is ticked. It is what inference becomes impossible when the detail is absent.
1. Reconstruct the population and assignment point
You should be able to follow participants from eligibility and recruitment through randomization. If the report only gives a final sample size, you cannot tell whether exclusions occurred before or after assignment, whether recruitment stopped early, or how representative the enrolled population was of the intended patients.
2. Read the intervention as a treatment strategy
The intervention is more than a product name. Dose, schedule, titration, training, co-interventions, rescue treatment, and permitted changes can all affect the contrast. Reported adherence and deviations help you understand whether the result is an effect of assignment or of receiving treatment as planned.
3. Make the treatment question visible
CONSORT 2025 discusses estimands but does not require every report to use the formal framework. Reviewers should still ask the underlying question: what outcome, in which population, over what time horizon, and how are events after randomization handled? A treatment switch, rescue therapy, or death may change the meaning of the effect without changing the randomization.
4. Inspect outcome measurement, not only outcome names
“Disease control” or “clinical response” is not a reproducible endpoint until the threshold, window, assessor, instrument, and adjudication rules are stated. A composite endpoint also needs its components and order of importance. If measurement differs by group or by follow-up intensity, randomization does not remove that problem.
5. Follow the missing outcomes
The flow diagram is not decorative. Reconcile the number randomized, treated, followed, analyzed, and included in each outcome. Ask why data are missing and whether the primary analysis uses all randomized participants, an available-case subset, imputation, or another rule. “Intention-to-treat” is a principle about preserving assignment, not a magic label that makes missing outcomes harmless.
6. Tie the analysis to the protocol
The primary analysis, adjustment variables, multiplicity rules, stopping decisions, and uncertainty intervals should be traceable to the protocol or statistical analysis plan. A post hoc analysis can be useful, but it should be named as such. Otherwise, readers cannot distinguish a prespecified test from a result selected after looking at the data.
7. Check the open-science trail
Registration details, protocol and analysis-plan access, data or code-sharing statements, funding, and conflicts are not administrative footnotes. They let a reader compare the published report with the planned study and judge what remains independently auditable. Missing access is a transparency limitation; it is not by itself proof that results were changed.
A Clinical Example: “The Trial Was Negative”
Imagine a randomized trial of a post-discharge follow-up program. The abstract says the program did not reduce 30-day readmission. The main table reports a risk ratio, but the paper does not explain how many participants received the scheduled calls, how many crossed over to usual care, whether readmission was assessed from records or patient report, or how patients lost to follow-up were handled.
A CONSORT-oriented review changes the sentence you are willing to write. You may be able to say that random assignment to the program did not show a clear difference under the reported analysis. You may not be able to say that receiving the program had no effect, that the program was ineffective for adherent patients, or that the result generalizes to all discharged patients. Those are different claims requiring different information.
| Report says | Reviewer can infer | Still needs caution about |
|---|---|---|
| Randomized 1:1 | Assignment was intended to create comparable groups. | Recruitment, concealment, post-randomization exclusions, and implementation. |
| No difference in readmission | The reported contrast and uncertainty under the stated analysis. | Treatment received, missing outcomes, endpoint ascertainment, and precision. |
| CONSORT checklist completed | More reporting detail should be available for appraisal. | Whether the design was valid, the result was unbiased, or the effect is clinically important. |
How to Use the Checklist Without Turning It into a Score
- Start with the claim. Write the strongest sentence the authors appear to want readers to believe.
- Trace it backward. Identify the population, assignment, treatment version, outcome, time horizon, and analysis that would have to be clear for that sentence to be defensible.
- Mark the missing link. Use CONSORT 2025 to find the reporting item that should make that link inspectable.
- Separate request from verdict. Ask the authors to clarify or provide the missing detail before treating ambiguity as evidence of a flawed trial.
- Use the right extension. A cluster trial, pragmatic trial, non-inferiority trial, or harms analysis needs more than the core parallel-group checklist.
This approach makes the checklist do useful methodological work. It turns “the paper is incomplete” into a precise question about which claim cannot yet be audited and what information would change your judgment.
Why This Matters for Aqrab
Aqrab is built for the gap between a manuscript that looks polished and a methods section that is actually inspectable. It can help you pressure-test whether a trial report supports the claim it makes, while keeping reporting omissions, design limitations, and analysis choices distinct.
Paste a protocol, statistical analysis plan, or trial manuscript into Aqrab Try for a structured critique. If you are building a repeatable review workflow, explore the developer tools to put the same questions upstream of publication decisions.
Methods Anchors
The checklist and scope follow the CONSORT 2025 statement. The rationale and discussion of estimands, intercurrent events, and reporting detail follow the CONSORT 2025 explanation and elaboration. Use the relevant CONSORT extension when the trial design or outcome requires additional reporting items.
Keep reading
Don't stop at one method.
Good methods judgment comes from contrast. Read the neighboring guides, see where the assumptions diverge, and avoid treating every observational problem like it needs the same hammer.
Fragility Index: When One or Two Events Carry More Confidence Than They Should
A practical guide to the fragility index for clinical researchers. Covers event-flip sensitivity, loss to follow-up, effect-size context, and what reviewers should demand before trusting a barely significant trial.
Hierarchical Testing in Clinical Trials: When a Significant Secondary Endpoint Is Still Descriptive
A practical hierarchical testing guide for clinical researchers. Reconstruct the prespecified testing path before treating a small p-value on a secondary endpoint as confirmatory evidence.
Randomized Withdrawal Trials: Why a Relapse-Prevention Win Is Not a New-Patient Effect
A practical randomized withdrawal trial guide for clinical researchers. Audit the run-in, responder enrichment, withdrawal contrast, safety, and target population before generalizing a maintenance-effect claim.